Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Bemcentinib with Pembrolizumab, Carboplatin, and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with STK11 Mutation

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC), specifically the advanced or metastatic form that is non-squamous. The study is particularly interested in cases with or without a mutation in the STK11 gene. The treatment being tested involves a combination of medications, including Bemcentinib, which is taken orally in capsule form, and a group of drugs used in chemoimmunotherapy. These include Pembrolizumab, Carboplatin, and Pemetrexed, all of which are administered through an intravenous infusion.

The purpose of the study is to evaluate the safety and effectiveness of this combination treatment. Participants will receive the treatment as a first-line option, meaning it is the initial treatment given for their cancer. The study will be conducted in two phases. The first phase will focus on determining the safety and appropriate dosage of the treatment combination. The second phase will assess how well the treatment works in reducing the size of the cancer or controlling its growth, especially in patients with the STK11 mutation.

Throughout the study, participants will be monitored for any side effects and the overall response of their cancer to the treatment. The study aims to provide valuable information on the potential benefits of combining Bemcentinib with standard chemoimmunotherapy drugs for treating advanced NSCLC. The trial is expected to continue until 2025, with the goal of improving treatment options for patients with this type of lung cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and a physical examination.

    Eligibility is based on having advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable mutations or with an STK11 mutation.

  2. Step 2

    Treatment cycle 1

    The first treatment cycle begins with the administration of medications. This includes pemetrexed and carboplatin given through an intravenous (IV) infusion.

    Additionally, bemcentinib is taken orally in capsule form at a dose of 100 mg.

  3. Step 3

    Treatment cycle 2

    In the second cycle, the same medications are administered. Pemetrexed and carboplatin are given intravenously.

    The oral dose of bemcentinib is adjusted to 75 mg.

  4. Step 4

    Treatment cycle 3

    The third cycle involves the administration of pemetrexed and pembrolizumab intravenously.

    The oral dose of bemcentinib is further adjusted to 50 mg.

  5. Step 5

    Ongoing assessment

    Throughout the trial, regular assessments are conducted to monitor the body's response to the treatment.

    These assessments include imaging tests and laboratory evaluations to track the progress of the disease and any side effects.

  6. Step 6

    Completion of trial

    The trial is expected to continue until October 2025, with regular follow-ups to evaluate the effectiveness and safety of the treatment.

    The primary goal is to determine the safety and tolerability of the treatment combination, as well as its impact on tumor activity.

Who can join the trial?

6 criteria

  • The person must provide written permission to join the study before any tests or procedures begin. If the person cannot do this, a legally acceptable representative can provide permission.
  • The person must be at least 18 years old on the day they sign the permission form.
  • The person must have a confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with current treatments. This applies to Phase 1b of the study, regardless of PD-L1 status and without specific genetic changes that can be targeted by treatments.
  • For Phase 2a of the study, the person must have a confirmed diagnosis of advanced or metastatic non-squamous NSCLC with a specific genetic change called the **STK11 mutation**, and the cancer cannot be cured with current treatments. This also applies regardless of PD-L1 status and without specific genetic changes that can be targeted by treatments.
  • If the person has received previous treatments like chemotherapy, immunotherapy, or radiotherapy with the aim to cure non-metastatic cancer, they must have had a break of at least 6 months since the last treatment before joining the study.
  • The person must have a disease that can be measured according to specific guidelines called **RECIST 1.1**. If the cancer is in an area that was previously treated with radiation, it can still be measured if it has shown signs of getting worse.

Who cannot join the trial?

10 criteria

  • Patients who have not received treatment for their advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with or without a specific genetic change called the STK11 mutation.
  • Patients with other types of lung cancer that are not non-squamous non-small cell lung cancer.
  • Patients who have already received treatment for their advanced or metastatic lung cancer.
  • Patients with lung cancer that has a different genetic change that can be targeted with specific treatments, known as actionable mutations.
  • Patients who are not in the age range specified for the study.
  • Patients who are not willing or able to follow the study procedures.
  • Patients who have other serious health conditions that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who are participating in another clinical trial at the same time.
  • Patients who have a history of certain other medical conditions that the study doctors think might affect the study results.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Bemcentinib

    is a medication being studied for its potential to enhance the effects of other cancer treatments. In this trial, it is combined with other therapies to see if it can improve outcomes for patients with advanced or metastatic non-squamous non-small cell lung cancer. Researchers are looking at how well patients tolerate this medication and its potential to help fight the cancer.

  • Pembrolizumab

    is an immunotherapy drug that helps the body's immune system recognize and attack cancer cells. It is used in this trial to see if it can work effectively with other treatments to improve the condition of patients with advanced lung cancer.

  • Carboplatin

    is a chemotherapy drug that works by damaging the DNA of cancer cells, which can stop them from growing and dividing. In this study, it is used in combination with other therapies to evaluate its effectiveness in treating advanced lung cancer.

  • Pemetrexed

    is another chemotherapy medication that interferes with the growth of cancer cells. It is used in this trial to see if it can help improve the treatment outcomes for patients with advanced non-squamous non-small cell lung cancer when used alongside other therapies.

What is already known about the treatment

Bemcentinib – Bemcentinib is administered orally and is currently being studied in clinical trials for its safety and effectiveness in treating advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), particularly in patients with or without an STK11 mutation. It is not yet widely used in standard medical practice, as it is still under investigation. The main therapeutic indication is for use in combination with other treatments for NSCLC. Bemcentinib works by inhibiting a specific protein involved in cancer cell survival and spread, potentially enhancing the effects of other cancer therapies. It is classified as a selective AXL kinase inhibitor, which targets pathways that help cancer cells grow and resist treatment.

Investigated diseases

Non-Small Cell Lung Cancer (NSCLC) – This is a type of lung cancer that includes several subtypes, such as adenocarcinoma and large cell carcinoma. It is characterized by the uncontrolled growth of cells in the lung tissues, leading to the formation of tumors. NSCLC is known for its slow progression compared to other types of lung cancer, but it can spread to other parts of the body if not managed. The disease is often diagnosed at an advanced stage, where it may have already metastasized. In some cases, genetic mutations like STK11 can influence the behavior and progression of the cancer.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-511007-41-00Protocol codeBGBC016Estimated enrolment64 patientsSponsorBergenbio ASA

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.